1,027 results match your criteria: "Service Hospitalo-Universitaire[Affiliation]"
Chest
December 2024
Service de Pneumologie, CHU Poitiers, Poitiers, France.
Background: A large number of symptomatic individuals with central sleep apnea (CSA) in clinical practice have an indication for adaptive servo-ventilation (ASV) therapy.
Research Question: What are the effects of ASV therapy on sleep quality and PROMs in patients with CSA across a range of devices and indications.
Methods: This prospective, multicenter, observational cohort study was conducted in France and enrolled participants from June 2017 to February 2020.
Front Psychiatry
November 2024
French Society for Biological Psychiatry and Neuropsychopharmacology, STEP Section (Stimulation Transcrânienne En Psychiatrie), Saint-Germain-en-Laye, France.
Over the past three decades, non-invasive brain stimulation (NIBS) techniques have gained worldwide attention and demonstrated therapeutic potential in various medical fields, particularly psychiatry. The emergence of these novel techniques has led to an increased need for robust training programs to provide practitioners, whether clinicians or scientists, with the necessary skills and knowledge. In response, a comprehensive training curriculum for NIBS in psychiatry has been developed in France.
View Article and Find Full Text PDFBJPsych Open
December 2024
Non Communicable Diseases and Trauma Division, Santé publique France, Paris, France; Department of Psychiatry, AP-HP, Louis Mourier Hospital, Paris, France; and INSERM Team 1 - UMR1266, Institute of Psychiatry and Neurosciences, Université de Paris, Paris, France.
Background: Assessing the risk of subsequent self-harm after hospitalisation for COVID-19 is critical for mental health care planning during and after the pandemic.
Aims: This study aims to compare the risk of admission to hospital for self-harm within 12 months following a COVID-19 hospitalisation during the first half of 2020, with the risk following hospitalisations for other reasons.
Method: Using the French administrative healthcare database, logistic regression models were employed to analyse data from patients admitted to hospitals in metropolitan France between January and June 2020.
Int Clin Psychopharmacol
January 2025
Université Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations (CESP), MOODS UMR1018, CESP-Inserm, Team Moods, Faculté de Médecine, Le Kremin-Bicêtre.
Orthop Traumatol Surg Res
November 2024
Service Hospitalo-Universitaire d'Orthopédie Traumatologie, Hôpital Nord, Chemin des Bourrely, 13015 Marseille, France.
Encephale
November 2024
Médecine de santé au travail, hopices civils de Lyon, Lyon, France.
Objectives: The COVID-19 pandemic had a huge impact on global mental health. Health care students, both as young people and regarding their student condition, were a more at-risk population. During the first and the third waves, two national surveys already found high levels of psychological distress (21 to 83% of severe psychological distress).
View Article and Find Full Text PDFStud Health Technol Inform
November 2024
Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, Rennes, France.
Polypharmacy (PP) and hyperpolypharmacy (HPP), are prevalent among cancer patients and are associated with an increased risk of drug-drug interactions (DDI) and potentially inappropriate medications (PIM). This study aimed to characterize PP, HPP, DDI, and PIM in patients with hematological malignancies hospitalized for hematopoietic stem cell transplantation (HSCT) by introducing a novel metric: cumulative drug exposure. Clinical data warehouse (CDW) records were employed to develop algorithms that quantified patients' cumulative exposure to these prescribing determinants during hospitalization.
View Article and Find Full Text PDFNephrol Ther
November 2024
Pôle Pharmacie, Service hospitalo-universitaire de pharmacie, Centre hospitalier universitaire de Rennes, 35000 Rennes, France
Context: Poor medication management can lead to adverse outcomes for transplant patients, including acute rejection and graft loss. In recent years, mobile applications have been proposed as innovative tools to improve patient treatment management.
Objective: This review aimed to systematically evaluate the available research evidence on the relationship between mobile applications and treatment management in transplant patients.
Crim Behav Ment Health
December 2024
UMD Henri Colin, EPS Paul Guiraud, Villejuif, France.
Background: Extended stays in specialist secure hospital units raise ethical concerns. While this topic has been investigated in various countries, there has been little research on it in France.
Aims: We aimed to study the length of stay of patients in the Henri Colin unit, a secure hospital unit in the Paris area and test relationships between length of stay and sociodemographic, clinical and legal features.
Atherosclerosis
January 2025
Laboratoire de Biométrie et Biologie Evolutive UMR CNRS 5558, Université Lyon 1, Université de Lyon, Villeurbanne, France; Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.
Background And Aims: Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation. Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend dose adjustment for statin treatment according to known SLCO1B1 genotype to reduce SAMS. We hypothesized that the association between SLCO1B1 genotype and SAMS is misestimated because of publication bias.
View Article and Find Full Text PDFPsychol Med
October 2024
MOODS Team, INSERM U1018, CESP, Université Paris-Saclay, Faculté de Medicine Paris-Saclay, Le Kremlin Bicêtre F-94275, France.
Background: Despite the growing interest in the prevalence and consequences of loneliness, the way it is measured still raises a number of questions. In particular, few studies have directly compared the psychometric properties of very short measures of loneliness to standard measures.
Methods: We conducted a large epidemiological study of midwife students ( = 1742) and performed a head-to-head comparison of the psychometric properties of the standard (20 items) and short version (3 items) of the UCLA Loneliness Scales (UCLA-LS).
Mol Psychiatry
October 2024
MOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Genetic factors influence the effect of its main treatment option, antidepressant drugs (ATD). The GRIK4 rs1954787(T>C) genetic polymorphism was associated with response following 1-3 months of ATD treatment in some studies, but not others.
View Article and Find Full Text PDFTherapie
October 2024
Hospices civils de Lyon, 69000 Lyon, France; Service universitaire d'addictologie de Lyon (SUAL), CH Le Vinatier, 69500 Bron, France; Équipe PSR(2), CRNL, UMR 5292 CNRS/1028 Inserm - université Lyon 1, 69500 Bron, France. Electronic address:
Aim: The long-acting buprenorphine Buvidal® is a recent type of opioid agonist treatment (OAT) used for opioid use disorder (OUD). It was initially suggested to preferentially use Buvidal® for specific OUD populations, including people in prison, or patients in recovery and on sublingual buprenorphine. We conducted a national study to examine whether the profile of patients treated with Buvidal® in France matched these initial recommendations.
View Article and Find Full Text PDFJ Psychosom Res
December 2024
Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Mood Center Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, Le Kremlin Bicêtre F-94275, France; MOODS Team, INSERM 1018, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Université Paris-Saclay, Faculté de Médecine Paris-Saclay, Le Kremlin Bicêtre F-94275, France.
Int J Surg
October 2024
Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA.
Background: Postoperative cognitive decline (POCD) is the predominant complication affecting patients over 60 years old following major surgery, yet its prediction and prevention remain challenging. Understanding the biological processes underlying the pathogenesis of POCD is essential for identifying mechanistic biomarkers to advance diagnostics and therapeutics. This study aimed to provide a comprehensive analysis of immune cell trajectories differentiating patients with and without POCD and to derive a predictive score enabling the identification of high-risk patients during the preoperative period.
View Article and Find Full Text PDFBiol Psychiatry
October 2024
Fondation Fondamental, Créteil, France; Centre Hospitalier Universitaire de Montpellier, Hôpital Lapeyronie, Psychiatric Emergency and Post Emergency Department, Pole Urgence, Montpellier, France; L'Institut de Génomique Fonctionnelle, Université de Montpellier, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Montpellier, France. Electronic address:
Bull Cancer
December 2024
Service hospitalo-universitaire de pneumologie, hôpital Louis-Pradel, hospices civils de Lyon, 69500 Bron, France. Electronic address:
PLoS Biol
September 2024
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Transl Psychiatry
September 2024
Institut Pasteur, Université Paris Cité, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 3571, Perception and Action Unit, F-75015, Paris, France.
Mol Psychiatry
September 2024
Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Mood Center Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre, Paris, Le Kremlin Bicêtre, France.
New-onset psychiatric disorders are frequent after COVID-19. We aim to determine whether acute COVID-19 severity markers can predict post-COVID new-onset psychiatric disorders. We conducted an electronic health records (EHR) cohort study of patients hospitalized for COVID-19 and without any known history of psychiatric disorders.
View Article and Find Full Text PDFBMC Pulm Med
September 2024
Thoracic Oncology Department, Université Paris Cité, CIC INSERM 1425, Institut du Cancer AP-HP.Nord, Hôpital Bichat-Claude Bernard, 46 Rue Henri Huchard, Paris, 75108, France.
Background: PARP inhibitors (PARPi) are used in the treatment of ovarian, breast, pancreatic, and prostate cancers. Pneumonitis has been identified as a potential side effect, with a higher meta-analysis-assessed risk for olaparib versus other PARPi. Olaparib-induced interstitial lung disease (O-ILD) was first described within the Japanese population, with few information available for Caucasian patients.
View Article and Find Full Text PDFMidwifery
December 2024
MOODS Team, INSERM U1018, CESP, Université Paris-Saclay, Faculté de Medicine Paris-Saclay, Le Kremlin Bicêtre F-94275, France; Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Mood Center Paris Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Hôpital de Bicêtre F-94275, France.
Background: Poor mental health in health students is a major public health issue, impacting personal quality of life and functioning, curriculum and care quality to patients.
Problem: Few studies to date have examined mental health in midwifery students.
Aim: To evaluate the midwifery students'mental health.
Biomed Pharmacother
October 2024
Univ Lyon, Université Claude Bernard University of Lyon 1, Equipe Evaluation et Modélisation des Effets Thérapeutiques, Laboratoire de Biométrie et Biologie Évolutive, UMR CNRS, 5558v LBBE, Lyon F-69100, France; Lyon Immunopathology Federation (LIFe), Hospices Civils de Lyon, Lyon F-69000, France; Service de rhumatologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite F69000, France; Service hospitalo-universitaire de pharmacotoxicologie, Hospices Civils de Lyon, Lyon F69000, France.
Lancet Respir Med
November 2024
Université Paris-Cité, Institut Cochin, CNRS, INSERM, Paris, France; Respiratory Medicine and Cystic Fibrosis National Reference Center, Hôpital Cochin, AP-HP, Paris, France; ERN-Lung CF network, Frankfurt, Germany.
Background: Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration (FDA) for people with cystic fibrosis with at least one of 177 rare variants. The aims of this study were to describe the clinical response to elexacaftor-tezacaftor-ivacaftor for people with cystic fibrosis without a F508del CFTR variant in France and to determine CFTR variant responsiveness to elexacaftor-tezacaftor-ivacaftor based on the observed clinical response.
View Article and Find Full Text PDF